Vertex Pharmaceuticals (VRTX) Intangibles (2009 - 2026)

Vertex Pharmaceuticals' Intangibles history runs 18 years deep, the most recent figure standing at $418.5 million for Q1 2026.

• In Q1 2026, Intangibles fell 5.15% year-over-year to $418.5 million; the TTM figure through Mar 2026 stood at $418.5 million (down 5.15% YoY), while the FY2025 annual figure was $424.2 million, down 48.64% from the prior year.
• Intangibles was $418.5 million for Q1 2026 at Vertex Pharmaceuticals, down from $424.2 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $839.9 million in Q4 2023 to a low of $387.0 million in Q2 2022.
• Historically, Intangibles has averaged $595.5 million across 5 years, with a median of $603.6 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Intangibles jumped 55.97% in 2023, then slumped 48.64% in 2025.
• A 5-year view of Intangibles shows it stood at $603.6 million in 2022, then jumped by 39.15% to $839.9 million in 2023, then retreated by 1.67% to $825.9 million in 2024, then plunged by 48.64% to $424.2 million in 2025, then retreated by 1.34% to $418.5 million in 2026.
• The last three Intangibles figures came in at $418.5 million (Q1 2026), $424.2 million (Q4 2025), and $429.8 million (Q3 2025), per Business Quant data.